Australia's most trusted
source of pharma news
Wednesday, 12 November 2025
Posted 26 September 2025 AM
Watch out, Novo and Lilly. Pfizer and Roche want a share of the obesity market.
Pfizer will pay an initial US$4.9 billion to buy New York-based Metsera and its portfolio of next-generation obesity drugs, the pharma giant announced this week, while Roche declared a goal to become a top three obesity company, with products on the market by 2030.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.